Clinical Trial Update: QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy [Phase 1, Phase 2]

View source ↗

Summary

The QUILT-3.047 trial evaluating ImmunityBio's NANT vaccine for head and neck squamous cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• NANT Head and Neck Squamous Cell Carcinoma Vaccine (NANT vaccine)

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: WITHDRAWN